超越默沙东K药,司美格鲁肽一季度登顶全球“药王”,礼来在美处方量超诺和诺德

时代财经
09 May

全球“药王”之战愈演愈烈。GLP-1“双雄”诺和诺德(NVO.US)与礼来制药(LLY.US)2025年一季报出炉。这一季度,诺和诺德王牌单品司美格鲁肽总销售量跃升全球首位,超过默沙东(MRK.US)的帕博利珠单抗(商品名:Keytruda/可瑞达,俗称“K药”),暂时坐上全球“药王”宝座。彼时在2024年,司美格鲁肽距离K药还有2亿美元的差距。而礼来也不甘落后,2025年第一季度,其美国肠促...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10